CareDx, a developer of products and services specifically for organ transplant, acquired MediGo, an organ-transplant supply chain and logistics company.
Terms of the deal announced on 25 July were
Medicare Covers Lung Transplant Test
CareDx recently announced that its AlloSure Lung donor-derived cell-free DNA (dd-cfDNA) molecular testing service will be covered by Medicare under an existing Medicare Local Coverage Determination for molecular testing for solid organ allograft rejection.
Lung transplant patients have one of the lowest survival rates among solid-organ transplant recipients; their five-year survival rate is about 53%, according to the Organ Procurement and Transplantation Network.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?